Oxford BioMedica PLC (OXBDF)

[marcusl2]

HTTPS://www.thetimes.co.uk/article/oxford-biomedica-clinches-second-gene-therapy-deal-wst3z8p5s



Alan Oscroft
Fool.co.uk15 February 2018

Important deal
Thursday’s news boosted Oxford Biomedica’s prospects, with the firm announcing “a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia.“

Bioverativ will gain access to Oxford’s LentiVector and manufacturing technologies, in a deal which is worth a $5m upfront payment coupled with “various milestone payments, potentially worth in excess of $100m” and royalties. I wonder if those Oxford Biomedica forecasts will be upgraded now?

I see Oxford Biomedica as a ‘picks and shovels’ operator in the gene and cell therapy business, offering technology that can be used for a variety of genetic therapies. Whichever treatments are eventually successful, companies which offer the development platforms should do well.

The market response has been a 7.5% share price rise (at the time of writing), but the full potential of this latest development might not have been fully understood. Oxford Biomedica looks a strong long-term buy to me.

HTTPS://uk.finance.yahoo.com/news/one-growth-stock-d-buy-132534311.html